NEW YORK, Sept. 17 (GenomeWeb News) - Epoch Biosciences of Bothell, Wash., today announced that it has licensed its Eclipse-brand dark quencher technology to Applied Biosystems.
Epoch will supply ABI its technology for integration into ABI's TaqMan probes for use in 5' nuclease assays. The license agreement covers ABI's use of the quencher technology for detection of microorganisms in the environment, Epoch said.
Epoch will receive license fees and royalties on sales of TaqMan probes containing its technology.
The Eclipse dark quencher technology helps improve signals in DNA probes by suppressing signals generated by fluorescent dyes.
Epoch has licensed the technology to ABI for use in other TaqMan products, as well as to Amersham Biosciences, Qiagen, Takara, Glen Research, and Third Wave Technologies.